Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meloxicam.

Roy Fleischmann1, Imran Iqbal, Gleb Slobodin

  • 1University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. royfleischmann@radiantresearch.com

Expert Opinion on Pharmacotherapy
|October 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR-T as a salvage treatment in polyrefractory RA.

Rheumatology (Oxford, England)·2026
Same author

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study.

RMD open·2026
Same author

Response to correspondence on 'Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study' by Mysler et al.

Annals of the rheumatic diseases·2026
Same author

Clinical Images: Bone Buds as Precursors to Ankylosis in Axial Spondyloarthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.

Annals of the rheumatic diseases·2026
Same author

Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous haematopoietic stem cell transplantation: a case series.

Rheumatology (Oxford, England)·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), effectively treats osteoarthritis with fewer gastrointestinal issues than traditional NSAIDs. It offers comparable efficacy and safety for pain relief.

Area of Science:

  • Pharmacology
  • Rheumatology

Background:

  • Meloxicam is an oral non-steroidal anti-inflammatory drug (NSAID) approved for osteoarthritis treatment.
  • It exhibits COX-2 preferential activity, particularly at lower therapeutic doses.

Purpose of the Study:

  • To evaluate the efficacy and safety of meloxicam in treating osteoarthritis.
  • To compare meloxicam's gastrointestinal toxicity with traditional NSAIDs.

Main Methods:

  • Clinical trials and meta-analysis were used to assess meloxicam's effectiveness.
  • Adverse events and gastrointestinal symptoms were compared to other NSAIDs like piroxicam, diclofenac, and naproxen.

Main Results:

  • Meloxicam demonstrated comparable efficacy to other NSAIDs in osteoarthritis treatment.

Related Experiment Videos

  • A meta-analysis indicated fewer gastrointestinal symptoms, perforations, obstructions, and bleeds with meloxicam compared to non-selective NSAIDs.
  • Adverse events such as peripheral edema and hypertension occurred at similar rates.

    • Conclusions:

    • Meloxicam is an effective NSAID for osteoarthritis with a potentially improved gastrointestinal safety profile.
    • Its COX-2 preferential nature may contribute to reduced gastrointestinal toxicity compared to traditional NSAIDs.